Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Growth in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 254,500 shares, a growth of 83.5% from the May 31st total of 138,700 shares. Based on an average daily volume of 839,200 shares, the days-to-cover ratio is currently 0.3 days.

Astellas Pharma Stock Down 0.6 %

Shares of OTCMKTS:ALPMY opened at $9.86 on Friday. The stock has a market capitalization of $17.84 billion, a P/E ratio of 140.86 and a beta of 0.39. Astellas Pharma has a 1 year low of $9.15 and a 1 year high of $15.90. The stock has a 50-day simple moving average of $9.76 and a 200-day simple moving average of $10.65. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.71 and a current ratio of 0.91.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings data on Thursday, April 25th. The company reported $0.11 earnings per share (EPS) for the quarter. Astellas Pharma had a net margin of 1.20% and a return on equity of 5.85%. The company had revenue of $2.79 billion during the quarter. Equities analysts forecast that Astellas Pharma will post 0.36 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.